"Intellectual property cannot be an obstacle to ending Covid-19 and to ensuring equitable and universal access to vaccines," the Spanish government said in an informal policy paper circulated Thursday evening. Its view is that consensus must be "urgently found on the proposal for a temporary waiver."
Spain’s position sets the stage for a tense debate when EU leaders meet Friday evening to discuss their response to the pandemic. The country is at odds with Europe’s biggest economy as well as drugmakers, who warned that such a move will harm efforts to stem the pandemic.
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
More disappointment for Orphazyme as FDA rejects Niemann Pick C application
The FDA have rejected an application for marketing authorization for Orphazyme's main drug candidate, arimoclomol, as a treatment for metabolic disease Niemann Pick C. The authority wants more data.
Orphazyme CEO silent on potential firings in wake of FDA rejection
The FDA rejection of Orphazyme's drug candidate in its main indication will trigger major cuts at the biotech firm, but CEO Christophe Bourdon has no comment on where they will be implemented and how hard the US organization will be hit.
Orphazyme cuts guidance following FDA setback
Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.
Top Orphazyme figure on FDA rejection: "It is very disappointing and very unexpected"
Biotech heavyweight Bo Jesper Hansen is very disappointed over the FDA rejection of Orphazyme's only drug candidate.
US OTC hearing aid channel back on Department of Health agenda
The US health department aims to have a hearing on publishing the regulatory framework for selling hearing aids over the course of the year.
Chief Physician - Clinical Innovation Centre, Novo Nordisk 
(Senior) Regulatory Science Specialist - IWA Consulting 
Associate Director, Biostatistics - Genmab 
Principal Biostatistician - ALK 
Regulatory affairs life cycle specialist 
Analytical Coordinator (Senior scientist) – Permanent position, Symphogen 
Employee for regulatory department 
Project Assistant, Translational medicine - Y-mAbs Therapeutics 
Clinical Supply Manager/Specialist - Lundbeck 
Senior CMC Expert/Senior CMC Project Manager - Klifo